SCHEMBL4118366

SCHEMBL4118366

COc1cccc(C(=O)c2cc(Br)ccc2F)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
MAPT P10636 6/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
STAT3 P40763 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 2/20 0.41
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
AR P10275 1/20 0.41
TP53 P04637 1/20 0.40
GSTA1 P08263 1/20 0.40
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5153184 0.84 CDC25B (0.48) KDM4ERXFP1MAPTNPC1RAB9A
SCHEMBL5153378 0.84 CDC25B (0.48) KDM4ERXFP1MAPTNPC1RAB9A
SCHEMBL5222966 0.75 KDM4E (0.39) KDM4ERXFP1MAPTNPC1RAB9A
SCHEMBL4126866 0.75 KEAP1 (0.49) NPC1RAB9ASMN1; SMN2ARHSD17B10
SCHEMBL1309695 0.75 LMNA (0.64) SMN1; SMN2KMT2A
SCHEMBL11244683 0.73 SMN1; SMN2 (0.51) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL4117906 0.72 GAA (0.51) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL181455 0.71 MAPT (0.63) RXFP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL4124662 0.71 RECQL (0.56) KDM4EALDH1A1KMT2AGAARECQL
SCHEMBL4119074 0.71 NPC1 (0.47) KDM4EMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR KDM4E 2123/4885RXFP1 679/4885MAPT 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.